|
WO2021037183A1
|
|
Prodrug compounds and uses thereof for treatment of cancer
|
|
US2021078970A1
|
|
Prodrugs of the tyrosine kinase inhibitor for treating cancer
|
|
WO2021037198A1
|
|
Deuterated compound and use thereof in cancer treatment
|
|
WO2021035360A1
|
|
Prodrugs of the tyrosine kinase inhibitor for treating cancer
|
|
US2020339615A1
|
|
Prodrugs of a cdk inhibitor for treating cancers
|
|
WO2020098492A1
|
|
A crystalline form of 3- ( (l-valyl) amino) -1-propanesulfonic acid
|
|
US2020078388A1
|
|
CD73 inhibitors and pharmaceutical uses thereof
|
|
WO2020051686A1
|
|
Cd73 inhibitors and pharmaceutical uses thereof
|
|
US2021053914A1
|
|
Crystalline form of 3- ((l-valyl) amino)) -3, 3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof
|
|
WO2019119117A1
|
|
Glucosamine derivatives for the prevention or treatment of joint disorders
|
|
US2019185502A1
|
|
Glucosamine derivatives and pharmaceutical uses thereof
|
|
US2018273471A1
|
|
Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereof
|
